UA126336C2 - Лікування раку - Google Patents

Лікування раку Download PDF

Info

Publication number
UA126336C2
UA126336C2 UAA201909567A UAA201909567A UA126336C2 UA 126336 C2 UA126336 C2 UA 126336C2 UA A201909567 A UAA201909567 A UA A201909567A UA A201909567 A UAA201909567 A UA A201909567A UA 126336 C2 UA126336 C2 UA 126336C2
Authority
UA
Ukraine
Prior art keywords
erdafitinib
treatment
cancer
serum
serum phosphate
Prior art date
Application number
UAA201909567A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кім Стейкенс
Ким Стейкенс
Руіксо Хуан Хосе Перес
Руиксо Хуан Хосе Перес
Порре Пітер Марі З. де
Порре Питер Мари З. де
Енджелі Нарайан Еведхені
Энджели Нарайан Эведхени
Іоанн Лорьо
Иоанн Лорьо
Арлен О. Сіфкер-Радтке
Арлен О. Сифкер-Радтке
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA126336(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of UA126336C2 publication Critical patent/UA126336C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
  • Prostheses (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
UAA201909567A 2017-02-06 2018-02-02 Лікування раку UA126336C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
UA126336C2 true UA126336C2 (uk) 2022-09-21

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201909567A UA126336C2 (uk) 2017-02-06 2018-02-02 Лікування раку

Country Status (26)

Country Link
US (2) US11077106B2 (https=)
EP (2) EP4286005A3 (https=)
JP (3) JP2020505425A (https=)
KR (2) KR20250069693A (https=)
CN (1) CN110198716A (https=)
AU (2) AU2018216969B2 (https=)
BR (1) BR112019016043A2 (https=)
CA (1) CA3049737A1 (https=)
DK (1) DK3576740T3 (https=)
ES (1) ES2953005T3 (https=)
FI (1) FI3576740T3 (https=)
HR (1) HRP20230697T1 (https=)
HU (1) HUE062453T2 (https=)
IL (1) IL268463A (https=)
JO (1) JOP20190190B1 (https=)
LT (1) LT3576740T (https=)
MX (2) MX2019009304A (https=)
NZ (2) NZ796822A (https=)
PH (1) PH12019501885A1 (https=)
PL (1) PL3576740T3 (https=)
RS (1) RS64778B1 (https=)
SG (2) SG11201907199QA (https=)
SI (1) SI3576740T1 (https=)
SM (1) SMT202300233T1 (https=)
TW (1) TWI874925B (https=)
UA (1) UA126336C2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
AU2020253827B2 (en) * 2019-03-29 2026-01-08 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202109854RA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MX2022009905A (es) * 2020-02-12 2022-08-25 Janssen Pharmaceutica Nv Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
IL324823A (en) * 2023-05-24 2026-01-01 Janssen Pharmaceutica Nv Treatment of locally advanced or metastatic urothelial carcinoma with ardefinitiv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment

Also Published As

Publication number Publication date
IL268463A (en) 2019-09-26
PL3576740T3 (pl) 2023-09-11
NZ755301A (en) 2025-12-19
MX2019009304A (es) 2019-09-19
BR112019016043A2 (pt) 2020-03-31
EP4286005A2 (en) 2023-12-06
ES2953005T3 (es) 2023-11-07
DK3576740T3 (da) 2023-07-24
NZ796822A (en) 2025-12-19
HUE062453T2 (hu) 2023-11-28
SI3576740T1 (sl) 2023-10-30
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
CN110198716A (zh) 2019-09-03
US20220110935A1 (en) 2022-04-14
US11077106B2 (en) 2021-08-03
JP7668777B2 (ja) 2025-04-25
EP3576740A1 (en) 2019-12-11
JP2020505425A (ja) 2020-02-20
EP3576740B1 (en) 2023-06-14
SMT202300233T1 (it) 2023-09-06
SG10202105110VA (en) 2021-06-29
HRP20230697T1 (hr) 2023-10-13
TWI874925B (zh) 2025-03-01
AU2018216969A1 (en) 2019-07-25
KR20190110581A (ko) 2019-09-30
AU2024201871A1 (en) 2024-04-11
AU2024201871B2 (en) 2026-02-26
RS64778B1 (sr) 2023-11-30
AU2018216969B2 (en) 2024-04-11
LT3576740T (lt) 2023-08-10
JP2025024064A (ja) 2025-02-19
JP2023022190A (ja) 2023-02-14
MX2022007955A (es) 2022-07-27
JOP20190190A1 (ar) 2019-08-04
SG11201907199QA (en) 2019-09-27
US20200022976A1 (en) 2020-01-23
EP4286005A3 (en) 2024-03-06
CA3049737A1 (en) 2018-08-09
FI3576740T3 (fi) 2023-08-31
JOP20190190B1 (ar) 2024-04-18
PH12019501885A1 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
UA126336C2 (uk) Лікування раку
WO2018141921A1 (en) Cancer treatment
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
TW202241440A (zh) 預防或治療抗腫瘤劑相關疾病或病症的方法
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
JP2026016402A (ja) 癌治療
JP7797543B2 (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2023175477A1 (en) Treatment of breast cancer with amcenestrant
HK40103983A (en) Cancer treatment
EA052711B1 (ru) Лечение рака
HK40013982A (en) Cancer treatment
HK40018978A (en) Cancer treatment
HK40018978B (en) Cancer treatment
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы